Table 1 Associations of 9 single-nucleotide polymorphisms in 8 age-related macular degeneration susceptibility genes with an additional treatment requirement after 3 monthly injections of ranibizumab in the discovery stage.
Gene | SNP | 1/2 | Additional treatment (−) (11/12/22) | Additional treatment ( + ) (11/12/22) | OR (95% CI) | P | OR (95% CI)* | P* |
|---|---|---|---|---|---|---|---|---|
ARMS2/HTRA1 | rs10490924 | G/T | 27/25/21 | 26/72/69 | 0.501 (0.201–0.338) | 0.00053 | 0.549 (0.323–0.807) | 0.0023 |
CFH | rs800292 | A/G | 10/27/36 | 12/79/76 | 0.939 (0.619–1.426) | 0.77 | 0.989 (0.641–1.526) | 0.96 |
rs1410996 | A/G | 10/33/30 | 16/82/69 | 0.909 (0.606–1.365) | 0.65 | 0.980 (0.634–1.515) | 0.93 | |
CETP | rs3764261 | A/C | 1/27/45 | 8/47/112 | 0.938 (0.574–1.532) | 0.80 | 0.859 (0.517–1.429) | 0.56 |
C2/CFB | rs547154 | T/G | 0/9/64 | 0/13/154 | 0.617 (0.258–1.476) | 0.27 | 0.713 (0.283–1.797) | 0.47 |
CFI | rs4698775 | G/T | 5/28/40 | 9/60/98 | 0.866 (0.553–1.356) | 0.53 | 0.919 (0.579–1.457) | 0.72 |
TGFBR1 | rs334353 | G/T | 14/34/25 | 38/77/52 | 1.145 (0.774–1.696) | 0.50 | 1.216 (0.817–1.809) | 0.33 |
APOE | rs4420638 | G/A | 0/10/60 | 0/32/130 | 1.441 (0.689–3.015) | 0.33 | 1.381 (0.626–3.044) | 0.41 |
VEGFA | rs943080 | C/T | 9/35/29 | 14/76/77 | 0.793 (0.527–1.195) | 0.27 | 0.791 (0.533–1.292) | 0.29 |
